The priority is to develop new cancer therapies and undertake early phase clinical trials that are fully informed by modern molecular and imaging technologies. These studies will be performed to the highest standards, consistent with the current regulatory environment, and data generated made available to benefit the wider scientific community.

There is particular expertise in trials of antibody-targeted therapy, vascular therapy, DNA binding agents, radiation therapy, photodynamic therapy & biomedical informatics

Translational research coordinated between the UCL Cancer Institute and biomedical sciences and phase I/II clinical trials facilities with dedicated laboratories, pharmacy and imaging.

A wide range of science and clinical expertise based in one of Europe's biggest concentrations of biomedical science.